Our previous work has demonstrated that DYRK1A positively regulates EGFR/Met via regulating the expression and activation of STAT3, and that suppression of DYRK1A enhances the anti-cancer activity of EGFR-TKIs in wild-type EGFR NSCLC cells via inhibiting the STAT3 signaling pathway20. This evidence concerns the gene STAT3 and cancer.